

<b>IN THE MATTER OF</b>	*	<b>BEFORE THE</b>
<b>COREY CASTON, PHARM TECH</b>	*	<b>STATE BOARD</b>
<b>Respondent</b>	*	<b>OF</b>
<b>Registration No.: T18557</b>	*	<b>PHARMACY</b>
	*	<b>Case No. PT-17-019</b>
* * * * *		

**ORDER FOR SUMMARY SUSPENSION**

Pursuant to Md. Code Ann., State Gov't. II ("SG") §10-226 (c) (2) (2014 Repl. Vol.), the State Board of Pharmacy (the "Board") hereby suspends the registration to practice as a Pharmacy Technician (Pharm Tech) in Maryland issued to **COREY CASTON** (the "Respondent"), under the Maryland Pharmacy Act (the "Act"), Md. Code Ann., Health Occupations II (Health Occ. II), §§ 12-101 *et seq.* (2014 Repl. Vol.). This Order is based on the following investigative findings, which the Board has reason to believe are true:

**INVESTIGATIVE FINDINGS<sup>1</sup>**

1. At all times relevant hereto, the Respondent was registered to practice as a Pharm Tech in Maryland. The Respondent was first registered on September 13, 2016. The Respondent's registration expires on July 31, 2018.

2. At all times relevant hereto, the Respondent was employed as a Pharm Tech at a chain pharmacy in Prince George's County, Maryland, hereinafter the "Pharmacy."<sup>2</sup>

---

<sup>1</sup>The allegations set forth herein are intended to provide the Respondent with notice of the Board's action. They are not intended as, and do not necessarily represent, a complete description of the evidence, either documentary or testimonial, to be offered against the Respondent in connection with these charges.

3. On or about November 21, 2016, the Board received initial notification of controlled substance theft from the Pharmacy indicating possible employee pilferage, with no additional information provided.

4. On December 30, 2016, the Board received additional email from the Pharmacy, along with a written statement from the Respondent admitting to stealing Alprazolam<sup>3</sup>, 2 mg, and Percocet<sup>4</sup>, 5mg, to sell, as well as theft of front-end merchandise.

5. The Pharmacy filled out a Drug Enforcement Administration (DEA) form of “Report of Theft or Loss of Controlled Substances which stated the following thefts/losses caused by the Respondent, *inter alia*:

- A. Alprazolam, 2mg 328 tablets;
- B. Oxycodone-Acetaminophen 5-325 mg<sup>5</sup> 86 tablets.

6. As a result of the thefts, the Respondent was terminated from employment with the Pharmacy on December 9, 2016, the date that the loss was discovered.

---

<sup>2</sup> For confidentially purposes, the names of pharmacies and all individuals referenced herein will not be identified by name in this document, but may be revealed to the Applicant by contacting the Administrative Prosecutor.

<sup>3</sup> Alprazolam, available under the trade name Xanax, is a potent, short-acting anxiolytic of the benzodiazepine class—a minor tranquilizer. It is commonly used for the treatment of anxiety disorders, especially of panic disorder, but also in the treatment of generalized anxiety disorder (GAD) or social anxiety disorder.

<sup>4</sup> Percocet contains a combination of acetaminophen and oxycodone. Oxycodone is an opioid pain medication. An opioid is sometimes called a narcotic. Acetaminophen is a less potent pain reliever that increases the effects of oxycodone. Percocet is used to relieve moderate to severe pain.

<sup>5</sup> 5 mg equals the amount of oxycodone in the medication; 325 mg equals the amount of acetaminophen in the medication.

**CONCLUSIONS OF LAW**

Based on the foregoing, the Board finds that the public health, safety or welfare imperatively requires emergency action, pursuant to SG II §10-226 (c) (2) (2014 Repl. Vol.).


**ORDER**

Based on the foregoing, it is therefore this 16<sup>th</sup> day of August, 2017, by a majority vote of a quorum of the State Board of Pharmacy, by authority granted to the Board by SG II §10-226(c) (2) (2014 Repl. Vol.), the registration held by the Respondent to practice as a Pharm Tech in Maryland, Registration No. T18557 is hereby **SUMMARILY SUSPENDED**; and be it further

ORDERED that, upon the Board's receipt of a written request from the Respondent, a Show Cause Hearing shall be scheduled within a reasonable time of said request, at which the Respondent will be given an opportunity to be heard as to whether the Summary Suspension should be continued, regarding the Respondent's fitness to practice as a Pharm Tech and the danger to the public; and be it further

ORDERED, that the Respondent shall immediately turn over to the Board his wall certificate and wallet-sized registration to practice as a Pharm Tech issued by the Board; and be it further

ORDERED, that this document constitutes a final Order of the Board and is, therefore, a public document for purposes of public disclosure, as required by Md. Code Ann., Gen. Prov. §§ 4-101 *et seq.* (2014 Vol.).

  
\_\_\_\_\_  
Deena Speights-Napata, Executive Director  
Board of Pharmacy

## **NOTICE OF HEARING**

A Show Cause hearing to determine whether the Summary Suspension shall be continued will be held before the Board at 4201 Patterson Avenue, Baltimore, 21215 following a written request by the Respondent for same.